The company trades and markets a variety of pharmaceutical products, including medicines and cosmetics, which are manufactured by third parties and sold under its own brand names to wholesale and retail customers.
The company lacks a durable moat as it operates primarily as a trading entity in a highly fragmented market with low barriers to entry. While it claims brand trust, the low net margins of approximately 4% and negative cash conversion suggest a lack of pricing power and significant competition from larger, integrated pharmaceutical players.
Capital has been primarily directed toward working capital and the acquisition of a 51.45% stake in Hetvi Lifesciences in 2025 to gain manufacturing capabilities. While revenue has grown, the negative cash conversion indicates that growth is being funded by stretching the balance sheet rather than organic cash flow.
The company collapsed under the weight of its own growth as the negative cash conversion cycle became a terminal drain on liquidity. By 2029, the aggressive expansion into manufacturing via Hetvi Lifesciences failed to yield the promised margins, instead saddling the firm with fixed costs it couldn't cover. As trade receivables ballooned and related-party loans were called in, the lack of organic cash flow forced a dilutive fire sale or insolvency, proving that revenue growth without cash is merely a slow-motion liquidation.
RichFakir rates Sunrest Lifescience Ltd's business quality as mediocre — 49/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Sunrest Lifescience Ltd is trading about 44% below our estimate of fair value; we rate its price cheap. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Sunrest Lifescience Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Sunrest Lifescience Ltd's fair value is about ₹70 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →